Study of the Inflammatory Microenvironment in Atypical Meningiomas

Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04761653

Enrollment

Registered

2021-02-21

Start date

2021-01-01

Completion date

2021-06-30

Last updated

2021-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical Meningioma

Brief summary

Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy. This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208). This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* primary diagnosis of atypical meningioma * surgery

Design outcomes

Primary

Measure	Time frame
Progression free survival	2-21 years

Secondary

Measure	Time frame
Overall survival	2-21 years

Countries

France

Outcome results